Form 8-K - Current report:
SEC Accession No. 0001837607-25-000013
Filing Date
2025-02-24
Accepted
2025-02-24 14:01:28
Documents
17
Period of Report
2025-02-24
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aeon-20250224x8k.htm   iXBRL 8-K 66060
2 EX-3.1 aeon-20250224xex3d1.htm EX-3.1 15470
3 EX-99 aeon-20250224xex99.htm EX-99 15434
4 GRAPHIC aeon-20250224xex99001.jpg GRAPHIC 3801
  Complete submission text file 0001837607-25-000013.txt   249784

Data Files

Seq Description Document Type Size
5 EX-101.SCH aeon-20250224.xsd EX-101.SCH 4043
6 EX-101.DEF aeon-20250224_def.xml EX-101.DEF 2868
7 EX-101.LAB aeon-20250224_lab.xml EX-101.LAB 18505
8 EX-101.PRE aeon-20250224_pre.xml EX-101.PRE 11069
19 EXTRACTED XBRL INSTANCE DOCUMENT aeon-20250224x8k_htm.xml XML 5241
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

EIN.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40021 | Film No.: 25655925
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)